Evidence map›Paper›PMID 37417007›Full record

ArticleTurkish journal of pharmaceutical sciences2023

Burak Bıyık, Sezen Yılmaz Sarıaltın, Alper Gökbulut, Tülay Çoban, Maksut Çoşkun

Open access · diamondAbstract read
In one paragraph

Article in Turkish journal of pharmaceutical sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Burak BıyıkThe Turkish Medicines and Medical Devices Agency, Ankara, Türkiye.ORCID 0000-0001-8717-2339
Sezen Yılmaz SarıaltınAnkara University, Faculty of Pharmacy, Department of Pharmaceutical Toxicology, Ankara, Türkiye.ORCID 0000-0002-8387-4146
Alper GökbulutAnkara University, Faculty of Pharmacy, Department of Pharmacognosy, Ankara, Türkiye.ORCID 0000-0001-8657-6016
Tülay ÇobanAnkara University, Faculty of Pharmacy, Department of Pharmaceutical Toxicology, Ankara, Türkiye.ORCID 0000-0002-9696-6613
Maksut ÇoşkunAnkara University, Faculty of Pharmacy, Department of Pharmaceutical Botany, Ankara, Türkiye.ORCID 0000-0002-2055-0849
Ankara University · TRPharmaceuticals and Medical Devices Agency · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Material and Methods: Plant material was collected in different seasons from the northwest of Türkiye. 2,2'-Azinobis-(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS) and 2,2-diphenyl-1-picrylhydrazyl (DPPH) free radical scavenging activities were investigated to assess antiradical and antioxidant potential of the extracts. Anti-inflammatory activity of the extracts was also tested using human red blood cell membrane stabilizing method. Folin-Ciocalteu test was conducted to determine the total phenolic content. Reverse phase-high performance liquid chromatography-photodiode array detector (RP-HPLC-PDA) analysis was performed. Results: Both methanol and aqueous extracts exhibited significant radical scavenging and anti-inflammatory activities compared with control ( Conclusion: To the best of our knowledge, the presence of rosmarinic acid in herbs and roots of

Indexed as

anti-inflammatory activityAntioxidant activityrosmarinic acidRP-HPLC-PDATrachystemon orientalis

Identifiers

PMID37417007
PMCPMC10337024
OpenAlexW4284710905

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.